CCKBR and neoplasm: CCK-2R specificity of [177Lu]Lu-(R)-DOTAGA-rhCCK-16 was evaluated via co-injection of an excess of the CCK2R-targeted compound, [natLu]Lu-DOTA-MGS5, which resulted in activity levels in the tumour < 1%.